Latest News and Press Releases

DUBLIN, Ireland, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Feb. 2, 2018 of...

DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the launch of Cystinosis United, an initiative created for people living with nephropathic...

DUBLIN, Ireland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its fourth-quarter and full-year 2017 financial results will be released on Wednesday, Feb....

-- Increases KRYSTEXXA® (pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ---- Increases Teprotumumab Estimated Peak Annual Net Sales to more than $750 Million ----...

DUBLIN, Ireland, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today announced that it has licensed the global rights to MEDI4945, a pre-clinical, genetically engineered...

DUBLIN, Ireland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on January 4, 2018 of...

DUBLIN, Ireland, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Jan. 1, 2018 of...

DUBLIN, Ireland, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for...

DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...

DUBLIN, Ireland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...